Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dagmar Schaub

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Medical Microbiology and Immunology|August 2, 2024
Carl Flügge, one of the last holistic hygienists and discoverer of droplet transmission of infectious diseasesPeter R Donald, Stefan H E Kaufmann, Dagmar Schaub, et al.
Pneumologie (Stuttgart, Germany)|May 23, 2024
[Everything under control?]Johanna Eggeling, Barbara Kalsdorf, Dagmar Schaub, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 26, 2023
Long-term treatment outcomes in patients with multidrug-resistant tuberculosisChristina Maier, Dumitru Chesov, Dagmar Schaub, et al.
Open Forum Infectious Diseases|June 29, 2026
Individualized Therapy Guided by Drug Susceptibility Testing for Multidrug-Resistant TuberculosisThomas Theo Brehm, Dagmar Schaub, Viola Dreyer, et al.
Frontiers in Immunology|June 29, 2026
PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapyJohanna Eggeling, Martina Sester, Christoph Lange, et al.
Pathogens & Immunity|June 28, 2024
A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant TuberculosisNika Zielinski, Dragos Baiceanu, Antonela Dragomir, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2021
Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA SequencingHans-Peter Grobbel, Matthias Merker, Niklas Köhler, et al.
The Lancet Regional Health. Europe|July 23, 2025
Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort studyYousra Kherabi, Ole Skouvig Pedersen, Christoph Lange, et al.
Tuberculosis (Edinburgh, Scotland)|February 13, 2026
Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation studyEmily Behrens, Niklas Köhler, Max Münchow, et al.
Pharmaceutics|November 25, 2023
A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant TuberculosisNiklas Köhler, Hande Karaköse, Hans-Peter Grobbel, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Medical Microbiology and Immunology|August 2, 2024
Carl Flügge, one of the last holistic hygienists and discoverer of droplet transmission of infectious diseasesPeter R Donald, Stefan H E Kaufmann, Dagmar Schaub, et al.
Pneumologie (Stuttgart, Germany)|May 23, 2024
[Everything under control?]Johanna Eggeling, Barbara Kalsdorf, Dagmar Schaub, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 26, 2023
Long-term treatment outcomes in patients with multidrug-resistant tuberculosisChristina Maier, Dumitru Chesov, Dagmar Schaub, et al.
Open Forum Infectious Diseases|June 29, 2026
Individualized Therapy Guided by Drug Susceptibility Testing for Multidrug-Resistant TuberculosisThomas Theo Brehm, Dagmar Schaub, Viola Dreyer, et al.
Frontiers in Immunology|June 29, 2026
PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapyJohanna Eggeling, Martina Sester, Christoph Lange, et al.
Pathogens & Immunity|June 28, 2024
A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant TuberculosisNika Zielinski, Dragos Baiceanu, Antonela Dragomir, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2021
Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA SequencingHans-Peter Grobbel, Matthias Merker, Niklas Köhler, et al.
The Lancet Regional Health. Europe|July 23, 2025
Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort studyYousra Kherabi, Ole Skouvig Pedersen, Christoph Lange, et al.
Tuberculosis (Edinburgh, Scotland)|February 13, 2026
Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation studyEmily Behrens, Niklas Köhler, Max Münchow, et al.
Pharmaceutics|November 25, 2023
A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant TuberculosisNiklas Köhler, Hande Karaköse, Hans-Peter Grobbel, et al.
Pageof 2